Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05573126Phase 1Recruiting

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Role: lead

NCT05443126Phase 1Recruiting

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Role: lead

NCT04581512Phase 1Recruiting

Study to Evaluate the Safety and Tolerability of EP0042

Role: lead

NCT07030478Phase 1Not Yet Recruiting

A Study to Evaluate the Safety and Tolerability of EP0089

Role: lead

NCT04669002Phase 2Completed

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Role: lead

NCT05411679Phase 2Withdrawn

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Role: lead

All 6 trials loaded